Futures looking bright enough for shades this morning. Good to have them on hand. Crude down fractionally. Gold comes in as "flat." Bitcoin down and draws closer to the $7,000 What Now? mark. No boost from President Xi on the horizon. How over-blown was that when it pushed Bitcoin close to the All Important $10,000 level? Boeing news brought to you by Boeing, of course. Elon Musk remains excommunicado. DuPont ($DD) is creating a new $45.4 billion consumer goods giant by merging its food and nutrition business with International Flavors & Fragrances. The deal announced Sunday values the DuPont unit at $26.2 billion. DuPont shareholders will retain a majority stake in the new entity, which will have a combined annual revenue of more than $11 billion. Beginning in 2020, 401(k) contribution limits are increasing. Workers under 50 will get to sock away up to $19,500, while those 50 and older will get to contribute up to $26,000. Keough account holders can contribute $57,000 in 2020, up from $56,000 in 2019. My wife has a Keough account and we appreciate the contribution level increase. At the top of the box office for three weeks, Disney's Frozen 2 has lost its crown to Jumanji: The Next Level, but not before the film crossed the $1B milestone. Disney isn't done yet. This coming weekend will feature the debut of Star Wars: The Rise of Skywalker, another movie that's all but guaranteed to pass the $1B mark. Long $DIS and wondering when the stock price will finally reflect the value of the company. China's ambassador to Germany has threatened Berlin with retaliation if it excludes Huawei as a supplier of 5G wireless equipment, citing the millions of vehicles German carmakers sell in China. Seems that warning shots have been fired. Stay tuned for updates on this one. Axsome Therapeutics is up 56% premarket on the heels of AXS-05, an oral, investigational NMDA receptor antagonist with multimodal activity, meeting the primary endpoint in the GEMINI Phase 3 trial in major depressive disorder (MDD). I have been adding some Bio-Tech updates to my comments lately. I have some long holdings like $EXEL and some speculative holdings in the sector. Novartis has decided to stop development of fevipiprant after a series of unsuccessful clinical trials. In October, the DP2 antagonist failed improve lung function in two Phase 3 studies in patients with moderate asthma. Those scoring at home may be interested in this news. Nothing on WeWork or Tesla this morning. Thank you. Phase One trade deal with China confirmed. I thought that the WSJ said that no such deal had been reached? Very strange. Politics and investing blurring the line once again.notes via user dcv.